CA2863240A1 - Compositions comprenant des polymeres reticules de liaison a des cations et utilisations associees - Google Patents

Compositions comprenant des polymeres reticules de liaison a des cations et utilisations associees Download PDF

Info

Publication number
CA2863240A1
CA2863240A1 CA2863240A CA2863240A CA2863240A1 CA 2863240 A1 CA2863240 A1 CA 2863240A1 CA 2863240 A CA2863240 A CA 2863240A CA 2863240 A CA2863240 A CA 2863240A CA 2863240 A1 CA2863240 A1 CA 2863240A1
Authority
CA
Canada
Prior art keywords
polymer
carboxylate groups
counterions
cations
magnesium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2863240A
Other languages
English (en)
Inventor
Alan D. Strickland
George M. Grass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorbent Therapeutics Inc
Original Assignee
Sorbent Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/020849 external-priority patent/WO2012097017A1/fr
Application filed by Sorbent Therapeutics Inc filed Critical Sorbent Therapeutics Inc
Priority claimed from PCT/US2012/047486 external-priority patent/WO2013106086A1/fr
Publication of CA2863240A1 publication Critical patent/CA2863240A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/288—Synthetic resins, e.g. polyvinylpyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2863240A 2012-01-10 2012-07-19 Compositions comprenant des polymeres reticules de liaison a des cations et utilisations associees Abandoned CA2863240A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2012/020849 WO2012097017A1 (fr) 2011-01-10 2012-01-10 Compositions comportant des polymères réticulés de liaison à des cations et des cations calcium et/ou magnésium, et leurs utilisations
USPCT/US2012/020849 2012-01-10
USPCT/US2012/038908 2012-05-21
PCT/US2012/038908 WO2013106072A1 (fr) 2012-01-10 2012-05-21 Compositions comprenant des polymères réticulés de liaison à des cations et utilisations associées
PCT/US2012/047486 WO2013106086A1 (fr) 2012-01-10 2012-07-19 Compositions comprenant des polymères réticulés de liaison à des cations et utilisations associées

Publications (1)

Publication Number Publication Date
CA2863240A1 true CA2863240A1 (fr) 2013-07-18

Family

ID=48782760

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2863240A Abandoned CA2863240A1 (fr) 2012-01-10 2012-07-19 Compositions comprenant des polymeres reticules de liaison a des cations et utilisations associees

Country Status (3)

Country Link
CA (1) CA2863240A1 (fr)
IL (1) IL233578A0 (fr)
WO (1) WO2013106072A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2971010B1 (fr) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation et administration de compositions de nucléosides, de nucléotides, et d'acides nucléiques modifiés
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3041938A1 (fr) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Polynucléotides circulaires
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
WO2016011226A1 (fr) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Polynucléotides chimériques
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
JP2017014206A (ja) 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
WO2018213731A1 (fr) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucléotides codant pour des polypeptides d'interleukine-12 (il12) ancrés et leurs utilisations
ES2952779T3 (es) 2017-05-18 2023-11-06 Modernatx Inc ARN mensajero modificado que comprende elementos de ARN funcionales
EP3638292A1 (fr) 2017-06-14 2020-04-22 ModernaTX, Inc. Polynucléotides codant pour le facteur viii de coagulation
EP3714045A1 (fr) 2017-11-22 2020-09-30 Modernatx, Inc. Polynucléotides codant pour des sous-unités alpha et bêta de propionyl-coa carboxylase pour le traitement de l'acidémie propionique
EP3714047A2 (fr) 2017-11-22 2020-09-30 ModernaTX, Inc. Polynucléotides codant pour la phénylalanine hydroxylase pour le traitement de la phénylcétonurie
EP3714048A1 (fr) 2017-11-22 2020-09-30 Modernatx, Inc. Polynucléotides codant pour l'ornithine transcarbamylase pour le traitement de troubles du cycle de l'urée
EP3735270A1 (fr) 2018-01-05 2020-11-11 Modernatx, Inc. Polynucléotides codant pour des anticorps anti-virus du chikungunya
WO2019226650A1 (fr) 2018-05-23 2019-11-28 Modernatx, Inc. Administration d'adn
WO2020023390A1 (fr) 2018-07-25 2020-01-30 Modernatx, Inc. Traitement enzymatique substitutif basé sur l'arnm combiné à un chaperon pharmacologique pour le traitement de troubles du stockage lysosomal
US20220110966A1 (en) 2018-09-02 2022-04-14 Modernatx, Inc. Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
US20220243182A1 (en) 2018-09-13 2022-08-04 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
US20230009009A1 (en) 2018-09-13 2023-01-12 Modernatx, Inc. Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
AU2019339430A1 (en) 2018-09-14 2021-04-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide A1 for the treatment of Crigler-Najjar Syndrome
WO2020069169A1 (fr) 2018-09-27 2020-04-02 Modernatx, Inc. Polynucléotides codant pour l'arginase 1 pour le traitement d'une déficience en arginase
CN114375190A (zh) 2019-05-08 2022-04-19 阿斯利康(瑞典)有限公司 用于皮肤和伤口的组合物及其使用方法
JP2023527875A (ja) 2020-06-01 2023-06-30 モダーナティエックス・インコーポレイテッド フェニルアラニンヒドロキシラーゼバリアント及びその使用
US20230406895A1 (en) 2020-11-13 2023-12-21 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
US20240216288A1 (en) 2021-03-24 2024-07-04 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
WO2022204369A1 (fr) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucléotides codant pour la méthylmalonyl-coa mutase pour le traitement de l'acidémie méthylmalonique
WO2022204390A1 (fr) 2021-03-24 2022-09-29 Modernatx, Inc. Nanoparticules lipidiques contenant des polynucléotides codant pour la phénylalanine hydroxylase et leurs utilisations
US20240207374A1 (en) 2021-03-24 2024-06-27 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
US20240189449A1 (en) 2021-03-24 2024-06-13 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
EP4355882A2 (fr) 2021-06-15 2024-04-24 Modernatx, Inc. Polynucléotides modifiés pour expression spécifique de type cellulaire ou micro-environnement
WO2022271776A1 (fr) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucléotides codant pour le polypeptide a1, de la famille de l'uridine diphosphate glycosyltransférase 1, pour le traitement du syndrome de crigler-najjar
WO2023056044A1 (fr) 2021-10-01 2023-04-06 Modernatx, Inc. Polynucléotides codant la relaxine pour le traitement de la fibrose et/ou d'une maladie cardiovasculaire
WO2023183909A2 (fr) 2022-03-25 2023-09-28 Modernatx, Inc. Polynucléotides codant pour des protéines du groupe de complémentation de l'anémie de fanconi, destinées au traitement de l'anémie de fanconi
WO2024026254A1 (fr) 2022-07-26 2024-02-01 Modernatx, Inc. Polynucléotides modifiés pour la régulation temporelle de l'expression

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991100A (en) 1974-01-02 1976-11-09 E. I. Du Pont De Nemours And Company Process for making esters of dibasic acids from acid by-products
US3935099A (en) 1974-04-03 1976-01-27 The United States Of America As Represented By The Secretary Of Agriculture Method of reducing water content of emulsions, suspensions, and dispersions with highly absorbent starch-containing polymeric compositions
US3997484A (en) 1974-04-03 1976-12-14 The United States Of America As Represented By The Secretary Of Agriculture Highly-absorbent starch-containing polymeric compositions
US4134863A (en) 1976-12-06 1979-01-16 The United States Of America As Represented By The Secretary Of Agriculture Highly absorbent graft copolymers of polyhydroxy polymers, acrylonitrile, and acrylic comonomers
US4295987A (en) 1979-12-26 1981-10-20 The Procter & Gamble Company Cross-linked sodium polyacrylate absorbent
US4654039A (en) 1985-06-18 1987-03-31 The Proctor & Gamble Company Hydrogel-forming polymer compositions for use in absorbent structures
US4861849A (en) 1988-01-15 1989-08-29 The Dow Chemical Company Sodium thiosulfate as part of a redox initiator system for the polymerization of water-swellable polymers
US5145906A (en) 1989-09-28 1992-09-08 Hoechst Celanese Corporation Super-absorbent polymer having improved absorbency properties
EP0459373A3 (en) 1990-05-31 1993-09-08 The B.F. Goodrich Company Bioadhesive carboxylic polymer composition and method relating thereto
EP1847271A3 (fr) * 2000-11-20 2008-08-06 Sorbent Therapeutics, Inc. Polymères hydroabsorbants et leur utilisation en tant que médicament
US7223827B1 (en) * 2004-02-27 2007-05-29 Fritz Industries, Inc Water control in a subsurface formation
CN101835500B (zh) * 2007-08-29 2014-05-28 吸附剂治疗学公司 具有可变抗衡离子含量的吸收性聚合物组合物及其制备方法和用途

Also Published As

Publication number Publication date
IL233578A0 (en) 2014-08-31
WO2013106072A1 (fr) 2013-07-18

Similar Documents

Publication Publication Date Title
CA2863240A1 (fr) Compositions comprenant des polymeres reticules de liaison a des cations et utilisations associees
AU2018256550B2 (en) Compositions comprising crossed linked cation-binding polymers
WO2013106086A1 (fr) Compositions comprenant des polymères réticulés de liaison à des cations et utilisations associées
WO2013106073A1 (fr) Compositions comprenant des polymères réticulés de liaison à des cations et utilisations associées
EP2187979B1 (fr) Compositions polymères absorbantes à contenu de contre-ion variable et leurs procédés de préparation et d'utilisation
AU2012205680A1 (en) Compositions comprising crosslinked cation- binding polymers and a base, uses thereof
WO2014015244A1 (fr) Composition comprenant des polymères réticulés à liaison cationique
CA2863233A1 (fr) Compositions comprenant des polymeres reticules de liaison a des cations et utilisations associees

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20151218